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Abstract: New cyclohexylidene 1,2,4,5-tetraoxanes with polar guanidine and 
urea based groups were synthesized and evaluated for their antimalarial activity 
against chloroquine resistant and susceptible Plasmodium falciparum strains. 
The derivatives showed moderate, nM range antimalarial activities and low 
cytotoxicity. The N-phenylurea derivative 24 exhibited the best resistance 
indices (RIW2 = 0.44, RITM91C235 = 0.80) and was not toxic against human nor-
mal peripheral blood mononuclear cells (IC50 > 200 μM). Seven derivatives 
were tested in vitro against four human cancer cell lines and they demonstrated 
high selectivity toward leukaemia K562 cells. One compound, derivative 21 
with a primary amino group, was the first tetraoxane tested in vivo against 
Toxoplasma gondii as another apicomplexan parasite. Subcutaneous adminis-
tration at a dose of 10 mg kg-1 day-1 for 8 days allowed the survival of 20 % of 
infected mice, thus demonstrating the high potential of tetraoxanes for the 
treatment of apicomplexan parasites. 
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INTRODUCTION 
Apicomplexan protozoa are single-celled parasites, with significant medical, 
veterinary and economic effects worldwide. From the aspect of human medicine, 
two apicomplexan infections are of major health concern – malaria, caused by 
Plasmodium spp., and toxoplasmosis, caused by Toxoplasma gondii. 
A potentially devastating disease, malaria represents an enormous public 
health problem in the majority of developing countries, further emphasized by 
the fact that nearly half of the world population is exposed to the infection.1 
Malaria may be caused by five Plasmodium species, P. falciparum, P. ovale, P. 
vivax, P. malariae and P. knowlesi, of which P. falciparum that causes cerebral 
malaria is the major threat. On a cellular level, all Plasmodium parasites contain 
acidic food vacuoles (FV), where digestion of haemoglobin occurs and it is gen-
erally accepted that the FV are the site of action for a number of quinoline-like 
drugs. The haem obtained from haemoglobin degradation is toxic to the parasite 
and is transformed into insoluble haemozoin pigment, while the globin is hydro-
lysed into individual amino acids. Antimalarial drugs active within FV appear to 
kill the parasite either by producing toxic free radicals2 or by blocking haemo-
zoin formation, as in the case of the 4-amino-7-chloroquinolines (ACQs).3 The 
development of widespread drug-resistance to chloroquine (CQ), the most suc-
cessful antimalarial drug, has resulted in severe health issues in malaria endemic 
regions. Although thorough investigation led to the realization that mutations in 
P. falciparum chloroquine resistant transporter (PfCRT), multidrug resistance 
protein 1 (PfMDR1) and multidrug resistance-associated protein (PfMRP) are 
responsible for the development of resistance of the malaria parasite against chlo-
roquine and its analogues,4 additional analysis appears necessary.5 Therefore, 
significant focus has been placed on the synthesis of peroxide antimalarials 
active in FV6 or interfering in NADPH balance acting as leuco-methylene blue 
(LMB) and FADH2 oxidisers,7 as well as on the development of new 4-amino-
quinolines,8 acridines9 and other molecules that prevent haem polymerisation.10 
T. gondii is an obligatory intracellular apicomplexan protozoan with world-
wide distribution. Globally, it has been estimated that one in three persons is 
infected with T. gondii. In the United States, nearly 25 % of the adult population 
has been infected with this organism,11 while most studies of European popul-
ations report 20−35 % seropositivity.12 However, in South America, these rates 
can reach 50−75 %.13 Individuals with a compromised immune system, such as 
HIV-infected persons and transplant recipients, are particularly prone to severe T. 
gondii induced disease, mainly as a result of reactivation of a previously latent 
infection.14 When primary T. gondii infection occurs during pregnancy, it can be 
vertically transmitted, which may result in intrauterine death, birth defects, or to 
late sequellae, such as ocular disease and mental retardation.  
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As intracellular pathogens, Plasmodium spp. and T. gondii both rely on the 
invasion of host cells for survival and proliferation. Since both parasites belong 
to the same apicomplexan phylum, they have common metabolic pathways and 
thus may be susceptible to same drugs for prevention or treatment.15–17 How-
ever, there are a number of differences between the two pathogens. During the 
asexual reproduction stage, P. falciparum exclusively targets human erythro-
cytes, whereas T. gondii can infect any cell in most vertebrates.17 And, while 
malaria is transmitted only via the mosquito vector or blood exchange, infection 
with T. gondii occurs via ingestion of sporulated oocysts shed into the environ-
ment by infected cats, or by consuming bradyzoites in the form of tissue cysts 
from infected animals. Current therapies for T. gondii include drugs which inhibit 
folate metabolism, protein synthesis, or disrupt electron transport.18,19 For the 
inhibition of folate metabolism, a combination of diaminopyrimidine antimal-
arials, such as trimethoprim 1 or pyrimethamine 2 (Fig. 1), and sulfonamides, 
such as sulfadiazine 3 (Fig. 1) or sulfamethoxazole, is the recommended therapy. 
This combination acts synergistically not only against T. gondii, but also against 
various bacterial and other parasitic microorganisms. In patients sensitive to sul-
fonamides, protein synthesis inhibitors such as macrolide and lincosamide anti-
biotics are the second line of drugs. Another antimalarial, atovaquone, an inhi-
bitor of mitochondrial electron-transport processes, is the drug of choice as third 
line therapy.20 In all these treatments, drug resistance, high cost, limited efficacy, 
and side effects21 often result in discontinuation of therapy. Therefore, new 
agents with better activity and safety profiles and that are less expensive are 
 
Fig. 1. Various inhibitors of the T. gondii parasite. 
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urgently needed.19 A variety of T. gondii inhibitors designed for different targets 
have been reported in the last few years, such as inhibitors of Ca-dependent 
protein kinase-1 (TgCDPK1),22,23 compounds which cause the disappearance of 
apicoplasts and plastid-like organelles,16 phosphodiesterase,17 purine nucleoside 
phosphorylase,18 and biosynthesis of pantothenic acid.24 Of these, outstanding 
activities were exhibited by TgCDPK1 inhibitors 4 and 5,22,23 and the inhibitor 
of the vitamin B5 biosynthetic pathway, derivative 6 (Fig. 1).24 
Outstanding examples of drugs active against both Plasmodium spp. and T. 
gondii parasites include artemisinin (7, ART, Fig. 2) and its semi-synthetic 
derivatives. It was established that their main mechanism of action is interfering 
in calcium homeostasis and triggering of micronema.25,26 ART and artemether 8 
exhibited 100 times better in vitro activity against T. gondii than trimethoprim 1, 
the current front-line drug.19 Other semi-synthetic artemisinin derivatives, inc-
luding 9,19 artemisone 10 or artemiside 11 have shown even better activities in 
the nM region (Fig. 2).27 These derivatives inhibit multiple steps in the T. gondii 
cycle,19,28 and the absence of activity of deoxyartemisinine confirmed the perox-
ide group as the pharmacophore.25 In vivo results are rare and incomplete,23 and 
only few studies are reliable. Thus, artemisinin showed complete clearance of 
parasitaemia after a 5-day treatment with 1.3 µg mL–1 day–1.29 An 8-day admin-
istration of artemiside at 10 mg kg–1 day–1 3 days after sulfadiazine treatment 
prolonged survival in 80 % of the mice, without toxic side-effects.24  
 
Fig. 2. Structures of artemisinin derivatives. 
Artemisinin and its derivatives,30 artemisone31 and other synthetic perox-
ides32,33 also exert potent in vitro and in vivo anticancer activities affecting 
diverse signalling pathways that regulate cell cycle, differentiation, apoptosis, 
invasion and angiogenesis in cancer cells.30 Artemisinins can functionally be 
clearly distinguished from the synthetic peroxides, in spite of the fact that they all 
share a common peroxide pharmacophore, which suggests that these molecules 
have multiple modes of action.33 Furthermore, it was found that synthetic and 
semi-synthetic peroxides exhibited specific activities against cancer cells. Thus, 
steroidal mixed tetraoxanes show highly specific activity toward UO31 renal 
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cancer cells,2b and artesunate against non-small cell lung cancer and colorectal 
cancer.34 
The high antimalarial activities of dicyclohexylidene tetraoxanes that pos-
sess polar end groups attached to one of the cyclohexane units35 encouraged us to 
explore the influence of modifications to the polar groups on their antimalarial 
and cytotoxic activities. For this, compound 21 was chosen since it showed the 
most promising in vivo activity against the malaria parasite.35c 
RESULTS AND DISCUSSIONS 
Synthesis 
Synthesis of targeted derivatives is presented in Schemes 1 and 2. The key 
intermediary tetraoxane amine 21 was prepared according to a previously des-
cribed procedure (Scheme 1).35c In brief, cyclohexane was transformed into gem-
dihydroperoxide 17 using 50 % H2O2 in the presence of Re2O7 as catalyst,36 
which was further coupled with benzyl 4-oxocyclohexanecarboxylate 1535a,37 
producing tetraoxane benzyl ester 18. The presence of the benzyl-group enabled 
a more efficacious purification of the crude product using a Biotage SP 
chromatography system. Reduction with LiAlH4 produced alcohol 19, which was 
transformed via the corresponding azide 20 into amine 21. Final derivatives 22–
25 (Scheme 2) were obtained from 21 and corresponding coupling reactants, in 
high to excellent yield (72–98 %). All derivatives were fully characterized and 
their purity, as determined by HPLC, was ≥95 %, with the exception of 
compound 23 that was 79–81 % pure. Full details are given in the Experimental 
and the Supplementary material to this paper. 
 
Scheme 1. Reaction pathway for the synthesis of derivative 21. 
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Scheme 2. Reaction pathway for the synthesis of derivatives 22–25. 
In the 1H-NMR spectra, all derivatives showed a characteristic signal at 
around 3.0 ppm for the methylene groups bonded to the polar groups (imida-
zoline, guanidine, urea or thiourea), and characteristic signals for the introduced 
polar groups: singlet at 3.38 ppm for the ethylene group in 22 and multiplets in 
the region 7.50–6.80 ppm for the aromatic protons in 24 and 25. In the 13C-NMR 
spectra, all derivatives showed signals for peroxy-acetal carbons in 107–108 ppm 
region and signals in the 45–50 ppm region for the methylene groups bonded to 
the polar groups. Additionally, a signal at 160 ppm for sp2 carbon in polar groups 
in 22, 23 and 24, and a signal at 180 ppm for 25 were present. Furthermore, 
aromatic carbons from the phenyl-groups in 24 and 25 appeared in the 117–140 
ppm region.  
Antimalarial activity  
Compounds were screened in vitro against four P. falciparum strains: D6 
(CQ susceptible (CQS) strain), W2 (CQ resistant (CQR) strain), TM91C235 (CQ 
and MFQ resistant) and TM90C2B (atovaquone resistant), following well-
established protocols.38 In brief, the Malaria SYBR Green I based fluorescence 
(MSF) assay is a microtiter plate drug sensitivity assay that uses the presence of 
malarial DNA as a measure of parasitic proliferation in the presence of anti-
malarial drugs or experimental compounds. The intercalation of SYBR Green I 
dye, and its resulting fluorescence, is relative to parasite growth, and a compound 
that inhibits the growth of the parasite will result in lower fluorescence inten-
sities. 
The antimalarial activities are presented in Table I. Tetraoxane 2135c was 
also screened here in order to enable a more reliable comparison to be drawn 
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with the activities of the new derivatives. All derivatives, with the exception of 
23, showed low nanomolar activities against all four strains. 
TABLE I. In vitro antimalarial activities against P. falciparum strains and cytotoxicity 
(PBMC) of tetraoxanes 21–25; n.t. – not tested 
Compd. P. falciparum, IC50 / nM PBMC, IC50 / μM RIh SIi 
D6a W2b TM91C235c TM90C2Bd (–)PHAe,f (+)PHAg
21 13.99 7.26 10.81 7.03 185.61 182.22 0.52/
0.77 
13265/25560/ 
17165/26388 
22 92.75 72.86 208.54 85.89 166.10 168.70 0.79/
2.25 
1791/2280/ 
796/1934 
23 243.84 494.37 1489.80 n.t. >200 >200 2.03/
6.11 
820/400/ 
134/– 
24 36.50 15.97 29.14 21.40 >200 >200 0.44/
0.80 
5480/12525/ 
6863/9343 
25 16.30 9.94 28.28 n.t. 32.74 32.01 0.61/
1.73 
2008/3295/ 
1158/– 
ARTj 6.66 3.79 16.90 6.23 n.t. n.t. 0.57/
2.54 
 
CQ 7.63 462.99 198.70 181.08 n.t. n.t. 60.70/
26.05
 
MQ 14.69 6.52 80.28 11.60 n.t. n.t. 0.44/
5.47 
 
aP. falciparum African D6 strain; bP. falciparum Indochina W2 strain; cP. falciparum TM91C235 strain; dP. 
falciparum TM90C2B strain; enon-stimulated with PHA; fPHA = phytohaemagglutinin, gstimulated with PHA; 
hresistance index (RI) is defined as the ratio of the IC50 values for the CQR versus CQS strain, W2/D6 and 
TM91C235/D6, respectively; iselectivity index (SI) is defined as the ratio of the IC50 values for PBMC
(–)PHA/D6, PBMC (–)PHA/W2, PBMC (–)PHA/TM91C235 and PBMC (–)PHA/TM90C2B, respectively;
javerage of greater than eight replicates, CQ = chloroquine, MQ = mefloquine 
Simultaneously, all derivatives except 23 were more active against the chlo-
roquine-resistant (CQR) W2 strain than against the chloroquine-susceptible 
(CQS) D6 strain, which could be seen from the favourable RI values. The deri-
vatives were somewhat less active against the multi-drug resistant TM91C235 
(CQR and MQR strain) in comparison with the activities exhibited toward the 
W2 strain. In addition, the corresponding RI values were less favourable, with the 
exceptions 21 and 25. However, three of the five derivatives were 7.4–2.8 times 
more active than MQ against the TM91C235 strain – 21, IC50 = 10.81 nM, 24, 
IC50 = 29.14 nM and 25, IC50 = 28.28 vs. MQ, IC50 = 80.28 nM. The most active 
derivative was 21 that showed exceptional activities against all the resistant 
strains. Even against the atovaquone resistant strain TM90C2B, this amine 
showed activities comparable with those of MQ. Removing the basic character of 
the terminal amino-group attenuates the anti-malarial activity, as seen in the case 
of compounds 21, 24 and 25. Transformation of the primary amino-group into 
N-phenyl urea or thiourea reduced the antimalarial activity. However, 25 pre-
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served high activity against the W2 strain, with an IC50 of 9.94 nM, which is 
comparable to those of MQ and 21 with values of 6.52 nM and 7.26 nM, 
respectively. On the other hand, increasing basic character of the terminal group 
did not increase the activity unconditionally. Introduction of more basic groups, 
such as imidazolidine or guanidine, led to a sharp decrease in activity. This was 
even more striking with the guanidine derivative 23, which was 17, 68 and 138 
times less active than 21 against D6, W2 and TM91C235 strains, respectively. 
Such sharp decreases in activity caused by more basic groups is in accordance to 
the behaviour observed with trioxolanes.39 Derivative 23 was also less active 
than 22, which makes it the least active compound within this series. Derivatives 
22 and 23 have same pKa values (Table S-I of the Supplementary material to this 
paper), which are two orders of magnitude higher than the pKa for 21, and 
correlations between pKa or log P values (Table S-I) with antimalarial activity 
could not be established.40 The derivatives were in general less active than ART 
against all four strains. Tetraoxane 21 was the only one with activities 
comparable with those of ART. However, two tetraoxanes 21 and 25 had better 
RI values compared to that of ART against multi-drug resistant strain TM91C235 
– 21, RI = 0.77 and 24, RI = 0.80 vs. ART, RI = 2.54. 
The toxicity of the compounds was estimated using human normal periphe-
ral blood mononuclear cells (PBMC), non-stimulated (PBMC (–)PHA) and sti-
mulated (PBMC (+) PHA) with PHA (Table I). In general, the PBMC assay for 
cytotoxicity estimation revealed that all compounds are well tolerated by normal 
immunocompetent cells, possessing IC50 ≥ 32 µM. In addition, high selectivity 
indices (SI) were obtained for all compounds toward all P. falciparum strains. 
Derivative 21 had the best SI indices, which were in the range 13000–26000, 
depending on the strain. The second best SI was exhibited by the urea derivative 
24, which had the lowest cytotoxicity >200 µM and moderate antimalarial 
activities in the range 16–36 nM. 
In vitro cytotoxic activity 
Cytotoxic activities of the new tetraoxanes and the previous compounds 21 
and 2035c were evaluated against four human cancer cell lines: cervix adenocar-
cinoma HeLa, melanoma Fem-x, breast adenocarcinoma MDA-MB-361 and 
chronic myelogenous leukaemia K562 cells. 
The intensities of the cytotoxic activities are given in Table II and Fig. 3. 
First, it should be emphasized that the tested tetraoxanes showed the strongest 
cytotoxic activities against myelogenous leukaemia K562 cells. The highest cyto-
toxicity against K562 cells was exerted by derivatives 25 with an IC50 of 6.15 
µM, 24 with 13.23 µM, and 18, 20 and 22 with an IC50 of ca. 18.5 µM. 
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TABLE II. In vitroa activities (IC50 / μM) of tetraoxanes against cancer cell lines (Fem-x, 
human melanoma cell line; HeLa, human cervical adenocarcinoma cell line; K562, myelo-
genous leukaemia cell line; MDA-MB-361, human breast adenocarcinoma cell line) and peri-
pheral blood mononuclear cells (PBMC), non-stimulated or stimulated with PHA (phyto-
haemagglutinin) 
Compd. Fem-x HeLa K562 MDA-MB--361 
PBMC
(–)PHA
PBMC
(+)PHA SIFem-x
a SIHeLa SIK562 SIMDA-MB-361 
21 79.75 63.56 33.68 >100 185.61 182.22 2 3 6 2 
18 31.86 27.01 18.84 73.92 >200 >200 6 7 11 3 
20 98.82 37.67 18.43 94.7 >200 >200 2 5 11 2 
22 43.84 34.56 18.38 80.29 166.10 168.70 4 5 9 2 
23 >100 75.66 81.49 90.91 >200 >200 2 3 2 2 
24 52.68 39.85 13.23 96.85 >200 >200 4 5 15 2 
25 15.67 10.51 6.15 41.13 32.74 32.01 2 3 5 1 
cis-Pt 8.10 7.89 5.64 >33.34 >66.67 >66.67 8 8 12 2 
aThe selectivity index (SI) is defined as the ratio of the IC50 for PBMC (–)PHA / cancer cell line 
 
Fig. 3. Survival (S%) of: A) cervical adenocarcinoma HeLa, B) melanoma Fem-x, C) myelo-
genous leukaemia K562 and D) breast adenocarcinoma MDA-MB-361 cells grown for 72h in 
the presence of increasing concentrations of the investigated tetraoxanes, 
determined by MTT test.  
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Against cervix adenocarcinoma HeLa cells, compounds 18, 20, 22, 24 and 
25 exerted pronounced cytotoxic actions with IC50 values in the range of 10.51 and 
39.85 µM. The highest cytotoxic effect was exhibited by derivative 25 with 
IC50 = 10.51 µM. Against melanoma Fem-x cells, compound 25 was the most 
active with an IC50 of 15.67 µM; derivative 18 exerted pronounced cytotoxic 
effects with IC50 value of 31.86 µM. Compounds 22 and 24 exerted moderate 
cytotoxic action, while the cytotoxic effects of the other derivatives were lower, 
with derivative 23 being the least active, showing an IC50 value higher than 100 
µM. All tested tetraoxanes exerted low cytotoxic actions against breast adeno-
carcinoma MDA-MB-361 cells with IC50 values >73.92 µM, except derivative 
25 which had moderate activity against this cell line, with an IC50 value of 41.13 
µM. Tetraoxane 23 with a guanidine group was the least active compound in this 
series, showing lowest activities towards all cell lines in comparison with other 
members of the series. 
All tetraoxanes exerted selective concentration-dependent cytotoxic activity 
against specific malignant cell lines, which was especially high against myelo-
genous leukaemia K562 cells. It is noteworthy that the cytotoxic actions of com-
pounds 21, 18, 22, 24 and 25 were notably higher against K562, HeLa and Fem-x 
cells than against MDA-MB-361 breast cancer cells, indicating selectivity in 
their anticancer action against specific malignant cell types. 
To further evaluate the anticancer potential of the tested tetraoxanes, their 
cytotoxic activities were examined against normal healthy peripheral blood 
mononuclear cells (PBMC), both resting and stimulated to proliferate by mitogen 
phytohaemagglutinin (PHA), Table II and Fig. 4. Each of the examined tetraox-
anes exerted remarkably higher cytotoxic activities against K562, HeLa and 
Fem-x malignant cell lines than against both non-stimulated and stimulated 
PBMC, indicating a significant specificity in their anticancer action. The highest 
 
Fig. 4. Survival of (A) resting PBMC and (B) PBMC stimulated to proliferate by PHA grown 
for 72h in the presence of increasing concentrations of the investigated tetraoxanes, 
determined by the MTT test. 
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selectivity in antitumor action was observed against myelogenous leukaemia 
K562 cells in comparison with normal healthy PBMC with tetraoxanes 18, 20 
and 24, which showed the highest SI values, 11, 11 and 15 respectively. In addi-
tion, the tested tetraoxanes showed good selectivity as follows: 18 and 24 against 
cervix adenocarcinoma HeLa and melanoma Fem-x cells, 20 against HeLa cells, 
and 22 against K562, HeLa and Fem-x cells. Low selectivity in the anticancer 
action of the tested tetraoxanes was observed against breast adenocarcinoma 
MDA-MB-361 cells, which showed the lowest sensitivity to the cytotoxic action 
of these compounds.  
In contrast to antimalarial activity, it could not be concluded that activities 
depend on the presence of a specific functional group. Rather, the activity was 
specific towards particular cell lines. However, in general, the obtained results 
showed that derivatives 21–23 with basic groups have lower activities. Deri-
vatives were less active than cisplatin with the exception of derivative 25. The 
thiourea derivative 25 was the most active tetraoxane in this series, with IC50 
values in the range 41–6.0 µM, which are the same as for cisplatin. However, the 
low SI of 25 for all tested cell lines makes this derivative less interesting, in spite 
of having good cytotoxic activities. Conversely, derivatives 18, 20 and 24 had SI 
values for the K562 cell line in the same range as that for cisplatin, which makes 
them very interesting candidates for further examinations.  
The mechanisms of cytotoxic action of 18, 20 and 24 were examined by cell 
cycle analysis and morphological assessment of cell death modalities induced by 
these tetraoxanes using fluorescence microscopy. The tested compounds at IC50 
concentrations induced time-dependent percentage increases of the target K562 
cells in the subG1 phase, as could be seen in Fig. 5. It is noteworthy that com-
pound 20 at the IC50 concentration caused the most remarkable increase in the 
percentage of K562 cells in the subG1 cell cycle phase after 48 h treatment. In 
addition, treatment with 2IC50 concentrations of three tetraoxanes resulted in an 
increase in the percentages of apoptotic subG1 K562 cells after 24 h exposure. 
After 48h, the percentages of subG1 K562 cells exposed to 2IC50 concentrations 
of 18, 20 and 24 were approximately 12 times higher compared to the control cell 
sample, pointing to a strong proapoptotic activity of these compounds. Exam-
ination of changes in the morphological features confirmed that the tested tetra-
oxanes triggered apoptosis in K562 leukaemia cells after 24 h treatment. Typical 
hallmarks of apoptotic K562 cells induced by tetraoxanes, such as shrinkage of 
the nucleus, chromatin condensation and fragmentation of the nucleus in addition 
to orange–red stained cells in the final stages of apoptosis are presented in Fig. 6. 
Prominent proapoptotic effects of tetraoxanes 18, 20 and 24 in addition to 
high selectivity in their anticancer activity against myelogenous leukaemia K562 
cells in comparison to normal immunocompetent PBMC, suggest significant 
anticancer potential of these compounds. 
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Fig. 5. Changes in the cell cycle phase distribution of K562 cells induced by the investigated 
tetraoxanes 18, 20 and 24 (tested concentrations corresponded to IC50 and 2IC50 values). 
C: control K562 cell sample. 
 
Fig. 6. Photomicrographs of acridine orange/ethidium bromide-stained control K562 cells and 
K562 cells treated with 2×IC50 concentrations of 18, 20 and 24, for 24 h. 
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In vivo activity against T. gondii 
Derivative 21 was chosen for examination of in vivo activity against T. 
gondii. The activity was examined in murine models of infection with tachyzoites 
of the highly virulent RH strain of T. gondii following a well-established pro-
tocol.41 The compound exhibited no visible toxicity as judged by the quality of 
fur, gait and general activity of the uninfected treated mice. The activity of 21 
was compared to that of ART. 
The results obtained in the treated animals are presented in Fig. 7. In the 
infection model where infection was established with 102 per mL, all untreated 
mice died between day 6 and day 9 p.i. (mean 8 days). Most importantly, treat-
ment with both 21 and ART in 10 mg kg–1 day–1 doses allowed survival of 20 % 
of infected treated mice after 15 days (Fig. 7a). Compared with the control mice, 
treatment with both drugs significantly prolonged survival, but the effect of 21 
was more pronounced (P = 0.014) than that of ART (P = 0.0413), whereas the 
effects of the two compounds were mutually comparable (P = 0.9086). 
 
Fig. 7. Survival of infected mice after treatment with 21 or ART; parasite concentration: 
a) 102 and b) 106 mL-1. 
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In mice infected with 106 mL–1, all untreated mice died within 5 days. Com-
pared to these, treatment with either 21 or ART significantly prolonged survival 
(P = 0.0092 and P = 0.0013, respectively) but did not afford complete protection. 
The antitoxoplasmatic activity of the two compounds was similar (P = 0.8358). 
Pathohistological analysis was performed on all surviving infected treated 
mice (four treated with 21 and two treated with ART), as well as on represent-
ative controls (non-infected treated mice), which were all sacrificed day 24 p.i. 
No pathological changes other than extramedullary haematopoiesis (character-
istic of these mice) and mild lymphocyte infiltration of the liver were revealed in 
both 21 and ART-treated mice, except for the finding of focal myocarditis in one 
ART-treated infected mouse. These results indicate no significant macroscopic or 
microscopic toxicity of the tested compounds, and moreover, show the potential 
of derivative 21 to clear T. gondii infection.  
EXPERIMENTAL 
Chemistry 
Melting points were determined on a Boetius PMHK or a Mel-Temp apparatus and were 
not corrected. Optical rotations were measured on a Rudolph Research analytical automatic 
polarimeter, Autopol IV in dichloromethane (DCM) or methanol (MeOH) as solvent. The IR 
spectra were recorded on a Perkin-Elmer FT-IR 1725X spectrophotometer. The 1H- and 
13C-NMR spectra were recorded on a Varian Gemini-200 spectrometer (at 200 and 50 MHz, 
respectively), and on a Bruker Ultrashield Advance III spectrometer (at 500 and 125 MHz, 
respectively) employing the indicated solvents (Supplementary material) using TMS as the 
internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants (J) 
in Hz. The ESI-MS spectra were recorded on an Agilent Technologies 6210 Time-Of-Flight 
LC-MS instrument in the positive ion mode with CH3CN/H2O 1/1 with 0.2 % HCOOH as the 
carrying solvent solution. The samples were dissolved in CH3CN or MeOH (HPLC grade 
purity). The selected values were as follows: capillary voltage, 4 kV; gas temperature, 350 °C; 
drying gas, 12.l min-1; nebulizer pressure, 310 kPa and fragmentator voltage, 70 V. Elemental 
analyses were realized on the Vario EL III- C,H,N,S/O elemental analyzer (Elementar 
Analysensysteme GmbH, Hanau, Germany). Thin-layer chromatography (TLC) was per-
formed on precoated Merck silica gel 60 F254 and RP-18 F254 plates. Column chromatography 
was performed on Lobar LichroPrep Si 60 (40–63 µm), or RP-18 (40–63 µm) columns 
coupled to a Waters RI 401 detector, and on Biotage SP1 system with a UV detector and 
FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with KP-SIL (40–63 µm, pore 
diameter 60 Å), or KP-C18-HS (40–63 µm, pore diameter 90 Å) as adsorbent. Compounds 18 
and 20–25 were analyzed for purity (HPLC) using an Agilent 1200 HPLC system equipped 
with Quat pump (G1311B), injector (G1329B) 1260 ALS, TCC 1260 (G1316A) and a 1260 
Infinity refractive index detector (RID) was. HPLC analyses were performed in two diverse 
systems. Method A: Zorbax Eclipse Plus C18, 4.6 mm×150 mm, 1.8 µm, S.N. USWKY01594 
was used as the stationary phase. The compounds were eluted using an isocratic protocol and 
eluent was made from water/MeOH, 30/70 (V/V). The compounds were dissolved in metha-
nol; the final concentrations were 0.5 mg mL-1. Method B: Poroshell 120 EC-C18, 4.6 mm×50 
mm, 2.7 µm, S.N. USCFU07797 was used as the stationary phase. The compounds were 
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eluted using an isocratic protocol and the eluent was made from water/MeOH, 30/70 (V/V). 
The compounds were dissolved in methanol; the final concentrations were 0.5 mg mL-1. 
Synthetic procedures 
Benzyl 7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylate (18). Into ice-cold 
(ice–water mixture) solution of gem-dihydroperoxide 17 (412.7 mg, 2.53 mmol) and ketone 
15 (374.8 mg, 2.53 mmol) in CH2Cl2 (5 mL), under intensive stirring, precooled freshly 
prepared solution of conc. H2SO4/CH3CN (1/10, V/V, 1.82 mL) was added dropwise. After 
one hour stirring at the same temperature, the reaction was quenched with water and the layers 
were separated. Water layer was extracted with CH2Cl2 (3×50 mL). The combined organic 
layers were washed with sat. NaHCO3 (3×20 mL), brine (2×10 mL) and dried over anh. 
Na2SO4. The solvent was removed under reduce pressure and the product was isolated after 
column chromatography purification (dry-flash, SiO2-column, eluent hexane/EtOAc, gradient 
97/3 → 9/1). Yield: 241.9 mg (26 %), as an amorphous powder. 
N-(7,8,15,16-Tetraoxadispiro[5.2.5.2]hexadec-3-ylmethyl)-4,5-dihydro-1H-imidazol-2- 
-amine (22). A mixture of 21 (100.0 mg, 0.39 mmol), I (142.2 mg, 0.58 mmol) and Et3N (0.5 
mL) in methanol (3 mL) was stirred under an inert atmosphere (Ar) for 3 days at 70 °C. The 
solvent was evaporated, the residue dissolved in CH2Cl2, 10 % NaOH solution added and the 
mixture intensively shaken. The layers were separated, the organic layer was washed once 
with water, once with brine and dried over anh. Na2SO4. The solvent was removed under 
reduce pressure and the product isolated after column chromatography purification (Lobar, 
SiO2-column A, eluent CH2Cl2/CH3OH sat. NH3 = 1/1). Yield: 91 mg (72 %). 
1-(7,8,15,16-Tetraoxadispiro[5.2.5.2]hexadec-3-ylmethyl)guanidine (23). A mixture of 
21 (100.0 mg, 0.39 mmol), S-methylthiourea sulphate (162.0 mg, 0.58 mmol) and Et3N (0.5 
mL) in methanol (3 mL) was stirred at 70 °C under an inert atmosphere (Ar) for 3 days. Into 
the warm solution, methanol was added (10 mL) and the warm mixture was filtered, the 
solvent removed under reduce pressure and product isolated after column chromatography 
purification (dry-flash, SiO2-column, gradient CH2Cl2/MeOH, = 9/1 → 1/1) as a pale yellow 
oil that became solid with time. Yield: 108.6 mg (93 %). 
1-Phenyl-3-(7,8,15,16-tetraoxadispiro[5.2.5.2]hexadec-3-ylmethyl)urea (24). A mixture 
of 21 (150.0 mg, 0.58 mmol) and phenyl-isocyanate (63.4 μL, 0.58 mL) in CH2Cl2 (10 mL), 
was stirred at r.t. under an inert atmosphere (Ar) for 45 min. The solvent was evaporated and 
product isolated after column chromatography purification (dry-flash, SiO2-column, gradient 
hexane/EtOAc = 1/1 → EtOAc → EtOAc/MeOH = 7/3). Yield: 215 mg (98 %).  
1-Phenyl-3-(7,8,15,16-tetraoxadispiro[5.2.5.2]hexadec-3-ylmethyl)thiourea (25). A mix-
ture of 21 (78.2 mg, 0.30 mmol) and phenyl-isothiocyanate (35.57 μL, 0.30 mL) in CH2Cl2 
(15 mL) was stirred under an inert atmosphere at r.t. for 2 h. The solvent was removed under 
reduce pressure and the product isolated after column chromatography purification (dry-flash, 
SiO2-column, gradient hexane/EtOAc = 9/1 → EtOAc). Yield: 87.3 mg (73 %). 
In vitro antimalarial activity 
The in vitro antimalarial drug susceptibility screen is a modification of the procedures 
first published by Desjardins et al.42 with modifications developed by Milhous et al., the 
details of which are given in ref. 8b. All the synthesized aminoquinolines were screened in 
vitro against the P. falciparum strains CQ and MFQ, as well as the susceptible strain D6 
(clone of the Sierra I/UNC isolate), the CQ resistant but MFQ susceptible strain W2 (clone of 
the Indochina I isolate), and the CQ and MFQ resistant strain TM91C235 (clone of the South–
East Asian isolate), and TM90C2B (clone of the Thailand isolate). 
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Cytotoxic activity 
Reagents. Stock solutions of investigated tetraoxanes were prepared in dimethyl sul-
phoxide (DMSO) at concentrations of 10 mM and subsequently diluted with complete nutrient 
medium (RPMI-1640 without phenol red) supplemented with 3 mmol L-1 L-glutamine, 100 
µg mL-1 streptomycin, 100 IU mL-1 penicillin, 10 % heat inactivated foetal bovine serum 
(FBS), and 25 mM HEPES, and adjusted to pH 7.2 with bicarbonate solution. RPMI-1640, 
FBS, HEPES, and L-glutamine were purchased from Sigma–Aldrich, St. Louis, MO, USA. 
Cell cultures. Human cervical adenocarcinoma HeLa, human melanoma Fem-x and 
human breast adenocarcinoma MDA-MB-361 cells were cultured as a monolayer, while 
human chronic myelogenous leukaemia K562 cells were grown in a suspension in the com-
plete nutrient medium, at 37 °C in a humidified air atmosphere with 5 % CO2, as previously 
described.43  
Preparation of peripheral blood mononuclear cells (PBMC). PBMC were separated 
from whole heparinised blood (obtained from two healthy volunteers) by Histopaque®-1077 
(Sigma–Aldrich) density gradient centrifugation. Interface cells, washed three times with 
Haemaccel (aqueous solution supplemented with 145 mM Na+, 5.1 mM K+, 6.2 mM Ca2+, 
145 mM Cl- and 35 g L-1 gelatine polymers, pH 7.4), were counted and suspended in nutrient 
medium with 10 % FBS.43  
Treatment of human malignant cell lines. HeLa (2,000 cells per well), Fem-x (5,000 cells 
per well) and MDA-MB-361 cells (10,000 cells per well) were seeded into 96-well microtiter 
plates. Twenty hours later, after cell adherence, five different concentrations of the inves-
tigated compounds in complete nutrient medium were added to the cells (range 6.25–100 µM 
or 3.125–50 µM), except for the control cells to which nutrient medium only was added. K562 
cells (5,000 cells per well) were seeded two hours before addition of the investigated com-
pounds to obtain final concentrations within the above-mentioned range. All experiments were 
realised in triplicate. Cisplatin was used as a positive control.  
Treatment of PBMC from healthy donors. PBMC cells were seeded at a density of 
150,000 cells per well in nutrient medium only, or in the nutrient medium enriched with 5 µg 
mL-1 of phytohaemagglutinin (PHA – INEP, Belgrade, Serbia) in 96-well microtiter plates. 
Two hours later, five different concentrations of the investigated tetraoxanes were added to 
the wells with non-stimulated and PHA-stimulated PBMC (in order to obtain five final con-
centrations within the range of 12.5–200 µM). All experiments were realised in triplicate. Cis-
platin was used as a positive control.  
Determination of cell survival. Cell survival 72 h after addition of the drug was deter-
mined by the MTT test according to the method of Mosmann44 as modified by Ohno and 
Abe.45 Briefly, 10 µL of MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, 5 mg mL-1 in phosphate buffered saline) was added to each well.43 The samples 
were incubated for a further four hours at 37 °C in a humidified atmosphere with 5 % CO2. 
Then, 100 µL of 10 % SDS solution was added to the wells. The absorbance was measured at 
570 nm the next day. To obtain cell survival (S / %), the absorbance at 570 nm of a sample 
with cells grown in the presence of various concentrations of agent was divided by the absorb-
ance of the control sample (the absorbance of cells grown only in nutrient medium), implying 
that the absorbance of the blank was always subtracted from the absorbance of a corres-
ponding sample with target cells. The IC50 concentration was defined as the concentration of 
an agent inhibiting cell survival by 50 %, compared to the corresponding control. 
Cell cycle analysis. K562 cells were exposed to two different concentrations of the 
examined compounds 18, 20 and 24 (corresponding to the IC50 and 2IC50 values determined 
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after 72 h treatment) for 24 and 48 h. After incubation, the target cells were collected, washed 
and fixed in 70 % ethanol on ice. The cell samples were stored at −20 °C for at least one week 
before staining. The cells were collected by centrifugation, washed, resuspended in PBS 
containing RNase A at a final concentration of 200 μg mL-1 and incubated for 30 min at 37 
°C. Subsequently, the propidium iodide solution was added to the cells at a final concentration 
of 40 μg mL-1.43 
The phase distribution of the cell cycle was determined using a FACSCalibur flow 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The data (10,000 events collected for 
each sample) were analysed using CELLQuest software (BD Biosciences). 
Morphological evaluation of K562 cell death. To examine the mode of death of human 
chronic myelogenous leukaemia K562 cells induced by the investigated tetraoxanes, morpho-
logical analysis by microscopic examination of acridine orange/ethidium bromide-stained 
target cells was performed, as already described.43 The K562 cells were seeded in 6-well 
plates (200,000 cells per well) in complete nutrient medium. After 2 h, the cells were treated 
with the investigated compounds for 24 h at concentrations corresponding to double the IC50 
values obtained after 72 h treatments. After this period, the target cells were collected by 
centrifugation and stained with 20 µL of a mixture of acridine orange and ethidium bromide 
(3 μg mL-1 AO and 10 μg mL-1 EB in PBS) dyes, and visualized under a fluorescence micro-
scope – Carl Zeiss PALM MicroBeam with Axio Observer.Z1 using AxioCam MRm (filters 
Alexa 488 and Alexa 568). 
Anti-toxoplasmatic activity 
Mice. Female Swiss Webster mice (Medical Military Academy Animal Research Facil-
ity, Belgrade, Serbia) weighing 18 to 20 g at the beginning of each experiment were used. The 
mice were housed six to a cage and offered drinking water ad libitum. 
T. gondii. Tachyzoites of the virulent RH strain maintained through serial intraperitoneal 
(i.p.) passages were used. For the experimental infections, tachyzoites were harvested from 
mouse peritoneal fluids 72 h post infection and purified by centrifugation, cotton wool 
filtration, and needle extraction. The parasites were counted in a haemocytometer, and their 
numbers were adjusted to 2×106 mL-1 with saline. The suspensions were also serially 10-fold 
diluted, and 0.5-mL aliquots of 2×102 and 2×106 mL-1 dilutions were inoculated i.p. into fresh 
mice.  
Infected non-treated mice served as infection controls. Mice were randomly assigned 
into experimental groups and treated with 21 or ART. Both drugs were administered at a dose 
of 0.2 mg per mouse per day (10 mg kg-1 day-1), subcutaneously (s.c.) for 8 consecutive days 
starting from the day of infection (day 0). Survival of the mice was monitored for another 
week after the end of treatment, meaning a total follow-up period of 15 days post infection 
(p.i.). To control for drug side effects (toxicity), separate groups of non-infected animals were 
given 21 (10 mg kg-1 day-1) and ART (10 mg kg-1 day-1) in the same manner and duration as 
in the experimental groups. 
Statistical analysis 
The rates of survival in particular treatment groups were estimated by the Kaplan–Meier 
product limit method and compared by the log-rank test. The level of statistical significance 
was 0.05. 
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CONCLUSIONS 
Herein, the synthesis and biological activity of new cyclohexylidene 
mixed 1,2,4,5-tetraoxanes containing polar guanidine and urea based 
groups were reported. Four new tetraoxanes were tested in vitro against P. 
falciparum CQR and CQS strains. The derivatives showed moderate nano-
molar antimalarial activities, and differences in activities were clearly inf-
luenced by changes in the structures of the introduced polar groups. The 
N-phenylurea derivative 24 showed the best resistance indices (RIW2 = 
= 0.44, RITM91C235 = 0.80), the highest SI score against all four tested P. 
falciparum strains and the lowest toxicity against PBMC (IC50 > 200 μM). 
Seven tetraoxanes were tested in vitro against four human cancer cell lines 
and five of them showed pronounced cytotoxic effects against myelo-
genous leukaemia K562 cells in 6.15–18.84 μM concentrations with high 
SIK562 index. The amino-tetraoxane 21 was the first one evaluated for its 
anti T. gondii effect in vivo, in a murine model of acute toxoplasmosis. An 
8-day treatment at a dose of 10 mg kg–1 day–1 allowed survival of 20 % of 
the infected mice. The obtained results clearly showed the activity of the 
investigated tetraoxanes against acute murine toxoplasmosis, suggesting 
the potential of synthetic organic peroxides in T. gondii treatment. 
SUPPLEMENTARY MATERIAL 
Calculated pKa and log P values for derivatives 21–23, synthetic procedures for 
derivatives 13–17 and 19–21 and analytical data for derivatives 13–25 and HPLC chroma-
tograms for determination of the purity of tested compounds are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
ТЕТРАОКСАНИ КАО ИНХИБИТОРИ АПИКОМПЛЕКСНИХ ПАРАЗИТА Plasmodium 
falciparum И Toxoplasma gondii И АНТИ-КАНЦЕРСКИ МОЛЕКУЛИ 
ДЕЈАН М. ОПСЕНИЦА1, ЈЕЛЕНА РАДИВОЈЕВИЋ2, ИВАНА З. МАТИЋ3, ТИЈАНА ШТАЈНЕР4, 
СЛАВИЦА КНЕЖЕВИЋ-УШАЈ5, ОЛГИЦА ЂУРКОВИЋ-ЂАКОВИЋ4 и БОГДАН А. ШОЛАЈА6 
1Институт за хемију, технолохгију и металургију, Универзитет у Београду, Његошева 12, 11000 
Београд, 2Институт за молекуларну генетику и генетски инжењеринг, Универзитет у Београду, 
Војводе Степе 444a, п. пр. 23, 11010 Београд, 3Институт за онкологију и радиологију Србије, 
Пастерова 14, 11000 Београд, 4Национална референтна лабораторија за токсоплазмозу, Институт 
за медицинска истраживања, Универзитет у Београду, др Суботића 4, п. пр. 102, 11129 Београд, 
5Институт за патологију, Медицински факултет, Универзитет у Новом Саду, Хajдук Вељкова 3, 
21000 Нови Сад и 6Хемијски факултет, Универзитет у Београду, Студентски трг 12–16, 
п. пр. 51, 11158 Београд 
Синтетисана је група нових циклохексилиденских 1,2,4,5-тетраоксана који имају 
гванидино и уреидо поларне групе и испитана је њихова антималаријска активност 
према хлорокивин-резистентним и осетљивим сојевима Plasmodium falciparum. Деривати 
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показују умерене активности у nM опсегу и ниску цитотоксичност. Дериват N-фенил- 
-урее 24 има најбољи индекс резистенције (RIW2 = 0,44; RITM91C235 = 0,80) и није токсичан према хуманим нормалним мононуклеарним ћелијама периферне крви (IC50 
> 200 μM). Седам деривата је тестирано in vitro према четири хумане малигне ћелијске 
линије и показало је високу селективност према K562 ћелијама леукемије. Дериват 21 
који има примарну амино групу је први тетраоксан тестиран in vivo према још једном 
паразиту из филума Apicomplexa, Toxoplasma gondii. Приликом супкутаног администри-
рања, дневна доза од 10 mg kg-1 омогућила је преживљавање 20 % инфицираних 
мишева, што показује висок потенцијал тетраоксана за терапију инфекција изазваних 
апикомплексним паразитима.  
(Примљено 30. априла, ревидирано и прихваћено 22. јуна 2015) 
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